High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions

References

• Ferreri A J, Foppoli M, Martelli M, Pangalis G, Frezzato M, Cabras G, et al. Randomized phase II trial on primary chemotherapy (CHT) with high-dose methotrexate (MTX) alone or associated with high-dose cytarabine (ARAC) for patients with primary CNS lymphoma (PCNSL). Ann Oncol 2008; 19(Suppl. 4), iv104, (abstract #65)
   Google Scholar
• Ferreri A J, Foppoli M, Martelli M, Pangalis G, Frezzato M, Cabras G, et al. Randomized phase 2 trial on primary chemotherapy (CHT) with high-dose methotrexate (MTX) alone or associated with high-dose cytarabine (ARAC) for patients with primary CNS lymphoma (PCNSL). Haematologica 2008, 93(S1) p. 158 abstract 0397
   PubMed Web of Science ®Google Scholar
• Ferreri A J, Dell'Oro S, Foppoli M, Bernardi M, Brandes A A, Tosoni A, et al. MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. Neurology 2006; 66: 1435–1438
   PubMed Web of Science ®Google Scholar
• Khalfallah S, Stamatoullas A, Fruchart C, Proust F, Delangre T, Tilly H. Durable remission of a relapsing primary central nervous system lymphoma after autologous bone marrow transplantation. Bone Marrow Transplant 1996; 18: 1021–1023
   PubMed Web of Science ®Google Scholar
• Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 2001; 19: 742–749
   PubMed Web of Science ®Google Scholar
• Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol 2008; 26: 2512–2518
   PubMed Web of Science ®Google Scholar
• Brevet M, Garidi R, Gruson B, Royer B, Vaida I, Damaj G. First-line autologous stem cell transplantation in primary CNS lymphoma. Eur J Haematol 2005; 75: 288–292
   PubMed Web of Science ®Google Scholar
• Colombat P, Lemevel A, Bertrand P, Delwail V, Rachieru P, Brion A, et al. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant 2006; 38: 417–420
   PubMed Web of Science ®Google Scholar
• Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G, et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 2006; 24: 3865–3870
   PubMed Web of Science ®Google Scholar
• Illerhaus G, Müller F, Feuerhake F, Schäfer A O, Ostertag C, Finke J. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica 2008; 93: 147–148
   PubMed Web of Science ®Google Scholar
• Montemurro M, Kiefer T, Schüler F, Al-Ali H K, Wolf H H, Herbst R, et al. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study. Ann Oncol 2007; 18: 665–671
   PubMed Web of Science ®Google Scholar
• Abrey L E, Moskowitz C H, Mason W P, Crump M, Stewart D, Forsyth P, et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 2003; 21: 4151–4156
   PubMed Web of Science ®Google Scholar
• Cheng T, Forsyth P, Chaudhry A, Morris D, Glück S, Russell J A, et al. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant 2003; 31: 679–685
   PubMed Web of Science ®Google Scholar
• Fischer L, Thiel E, Klasen H A, Birkmann J, Jahnke K, Martus P, et al. Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol 2006; 17: 1141–1145
   PubMed Web of Science ®Google Scholar
• Voloschin A D, Betensky R, Wen P Y, Hochberg F, Batchelor T. Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neurooncol 2008; 86: 211–215
   PubMed Web of Science ®Google Scholar
• Reni M, Zaja F, Mason W, Perry J, Mazza E, Spina M, et al. Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer 2007; 96: 864–867
   PubMed Web of Science ®Google Scholar
• Plotkin S R, Betensky R A, Hochberg F H, Grossman S A, Lesser G J, Nabors L B, et al. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res 2004; 10: 5643–5646
   PubMed Web of Science ®Google Scholar
• Arellano-Rodrigo E, López-Guillermo A, Bessell E M, Nomdedeu B, Montserrat E, Graus F. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol 2003; 70: 219–224
   PubMed Web of Science ®Google Scholar
• Tyson R M, Siegal T, Doolittle N D, Lacy C, Kraemer D F, Neutwelt E A. Current status and future of relapsed primary central nervous system lymphoma (PCNSL). Leuk Lymphoma 2003; 44: 627–633
   PubMed Web of Science ®Google Scholar
• Reni M, Mazza E, Foppoli M, Ferreri A J. Primary central nervous system lymphomas: salvage treatment after failure to high-dose methotrexate. Cancer Lett 2007; 258: 165–170
   PubMed Web of Science ®Google Scholar
• Wiebe V J, Smith B R, DeGregorio M W, Rappeport J M. Pharmacology of agents used in bone marrow transplant conditioning regimens. Crit Rev Oncol Hematol 1992; 13: 241–270
   PubMed Web of Science ®Google Scholar